Rockwell Medical Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, executive compensation, auditor ratification, and a reverse stock split amendment, all of which were approved by strong majorities. No questions were raised by stakeholders, and final voting results will be filed with the SEC.
-
Q1 2026 saw improved gross margin and stable gross profit despite lower sales, with positive trends in adjusted EBITDA and net income. Guidance for 2026 projects $70–$75M in sales, 18–22% gross margin, and positive cash flow, supported by operational efficiencies and international growth.
Fiscal Year 2025
-
Profitability was maintained on an adjusted EBITDA basis in 2025, with gross margin reaching historic highs in Q4 and a strengthened cash position. Expanded customer agreements and rapid response to supply chain disruptions drove growth, with 2026 guidance projecting further profitability.
-
Q3 2025 saw stable sequential sales but a 44% year-over-year decline due to a major customer transition, with gross margin stabilizing and adjusted EBITDA turning positive. Diversification, new contracts, and a strengthened cash position support growth and margin improvement into 2026.
-
Q2 2025 saw a 38% revenue decline due to the largest customer transition, but gross margin held steady at 16% and cash flow from operations was positive. Over 80% of customers are now under long-term contracts, reducing concentration risk and positioning for future growth.
-
Q1 2025 saw a 17% revenue decline due to a major customer transition, but gross margin improved to 16%. Guidance for 2025 is reaffirmed, with new products and customer diversification expected to offset lost revenue. At-home dialysis and Latin America expansion are key growth drivers.
Fiscal Year 2024
-
Net sales grew 21% to $101.5 million in 2024, with gross margin improving to 17% and adjusted EBITDA turning positive. 2025 is expected to be a transition year due to the loss of the largest customer, but guidance targets $65–$70 million in sales and continued profitability efforts.
-
Record Q3 sales, gross profit, and margin were driven by strong customer demand and a special large order, resulting in sustained profitability and a strengthened cash position. Despite a forecasted revenue decline from its largest customer in 2025, the company expects to remain profitable and is actively pursuing new growth opportunities.
-
Q2 2024 saw record net sales, a return to profitability, and strong margin expansion, prompting raised full-year guidance. New product launches and strategic expansion in the West and at-home markets are expected to drive further growth.
-
The company is the second-largest US provider of dialysis concentrates, with a 20% market share and strong growth in revenue and margins. Strategic acquisitions, automation, and partnerships drive expansion, while profitability and cash flow are key priorities.